Oncology and Therapy : Impact Factor & More
eISSN: 2366-1089pISSN: 2366-1070
Open AccessShare this on:
Key Metrics
CiteScore 
0.3
H-Index
5
SJR
Q2Oncology
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Topics Covered on Oncology and Therapy
Oncology and Therapy Journal Specifications
| Overview | |
| Publisher | SPRINGER |
| Language | English |
| Frequency | Semi-annual |
| Article Processing Charges | EUR 4500 | USD 5600 | GBP 4100 |
| Publication Time | 6 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Semi-annual |
| Publication Start Year | 2016 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Publication Time | 6 |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Oncology and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncology and Therapy
Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era.
- 15 May 2026
- Oncology and therapy
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.
- 14 May 2026
- Oncology and therapy
Occupational Variation in Thyroid Cancer Incidence in the Nordic Countries.
- 13 May 2026
- Oncology and therapy
Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture.
- 7 May 2026
- Oncology and therapy
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.
- 3 May 2026
- Oncology and therapy
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.
- 18 Apr 2026
- Oncology and therapy
Repurposing Resmetirom to Suppress MASLD/MASH-HCC in the Dysmetabolic Era.
- 15 May 2026
- Oncology and therapy
A Comprehensive Review of the Role of Zanubrutinib for Patients with Chronic Lymphocytic Leukemia.
- 14 May 2026
- Oncology and therapy
Occupational Variation in Thyroid Cancer Incidence in the Nordic Countries.
- 13 May 2026
- Oncology and therapy
Augmenting Performance Status: A Preliminary Study of Objective Kinematic Assessment Using Motion Capture.
- 7 May 2026
- Oncology and therapy
Treatment Sequencing and Immunotherapy Rechallenge in Advanced Non-Small-Cell Lung Cancer: Final 24-Month Real-World Results from the French LIST Study.
- 3 May 2026
- Oncology and therapy
Real-World Description of Non-ICANS Neurologic Events Among Patients with Relapsed or Refractory Multiple Myeloma Treated with Ciltacabtagene Autoleucel Using Two Large US Databases.
- 18 Apr 2026
- Oncology and therapy
FAQs on Oncology and Therapy
How long has Oncology and Therapy been actively publishing? 
What is the publishing frequency of Oncology and Therapy?
How many articles did Oncology and Therapy publish last year?
What is the eISSN & pISSN for Oncology and Therapy?
What is Citescore for Oncology and Therapy?
What is the H Index for Oncology and Therapy ?
What is the SJR for Oncology and Therapy?
Who is the publisher of Oncology and Therapy?
